Clinical Trial Update: A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

This document announces a Phase 3 clinical trial comparing ABP 234 to pembrolizumab (Keytruda) in patients with advanced or metastatic non-squamous non-small ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABP-234 (pembrolizumab biosimilar)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Amgen | Conditions: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING